CE-Ventures Backs Aptadir in €40M Seed Round

CE-Ventures has backed Aptadir Therapeutics in a €40 million seed round, a financing that ranks among the largest biotech seed rounds in Europe, StreetInsider reported.

The size of the check is the story. Seed rounds in European biotech rarely reach eight figures in euros. A €40 million commitment at the earliest stage of a company's life puts Aptadir in rare company and signals that institutional capital is once again willing to write large checks before clinical data exists.

CE-Ventures, the venture arm tied to the Dubai-based Crescent Enterprises group, led its participation in the round, according to the report. The involvement of a Gulf-backed investor in a European life-sciences seed deal also marks a geographic shift. Capital from the Middle East has flowed increasingly into European technology over the past two years, and biotech is now drawing a share of that allocation.

Aptadir Therapeutics is the recipient of one of the largest seed financings the European biotech sector has seen, as StreetInsider characterized the deal. The report did not disclose the round's other participants, the company's valuation, or the intended use of proceeds.

What the deal does show is the state of the financing market. After two years in which early-stage biotech funding contracted across Europe, investors with long horizons and large balance sheets are moving back into the segment. Seed-stage capital is the riskiest layer of biotech finance. Drug development runs on decade-long timelines, high failure rates, and capital requirements that routinely stretch into the hundreds of millions before a product reaches the market. A €40 million seed round gives a company the runway to build a team, advance a platform, and push lead programs toward preclinical or clinical milestones without returning to market immediately.

The round's scale also reflects a broader trend in venture financing across sectors: larger, fewer rounds. Investors have concentrated capital in fewer companies, writing bigger checks to back founders they believe can dominate a category. In biotech, that dynamic plays out at the seed stage more acutely than in software, because the cost of building a credible drug-discovery operation — labs, scientists, intellectual property, and preclinical studies — is front-loaded.

For CE-Ventures, the investment extends a portfolio strategy that reaches beyond the Gulf region's traditional sectors of logistics, energy, and infrastructure. Crescent Enterprises operates across multiple industries, and its venture arm has directed capital toward technology and healthcare targets. The Aptadir deal confirms life sciences as a destination for that capital in Europe.

European biotech has needed the support. The sector's financing environment tightened sharply as interest rates rose and public-market exits narrowed starting in 2022. Many venture firms retrenched to later-stage assets or existing portfolios. Seed-stage companies faced the sharpest squeeze, because they offer investors no clinical data, no revenue, and long timelines to liquidity. Rounds of this size at this stage were scarce through the downturn.

A €40 million seed round does not guarantee success, and the report offers no details on Aptadir's pipeline, targets, or development timeline. What it does establish is that at least one well-capitalized investor judges the current moment right to place a large early-stage bet on European drug discovery. The round's ranking among Europe's largest biotech seed financings — as reported by StreetInsider — sets a benchmark that other early-stage companies and their backers will now measure themselves against.